PRODUCT INFORMATION



Doxycycline-d₃ (hyclate)

Item No. 28528

Formal Name: (4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-

1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12apentahydroxy-(6-methyl-d)-1,11-dioxo-2naphthacene-4,6-d2-carboxamide, hydrochloride,

compd. with ethanol, hydrate (2:2:1:X)

MF: $2[C_{22}H_{21}D_3N_2O_8] \bullet 2HCI \bullet XH_2O \bullet C_2H_6O$

FW: 894.9


Chemical Purity: ≥95% (Doxycycline)

Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₃); \leq 1% d₀

Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Doxycycline-d₂ (hyclate) is intended for use as an internal standard for the quantification of doxycycline (Item No. 14422) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Doxycycline-d₃ (hyclate) is supplied as a solid. A stock solution may be made by dissolving the doxycycline-d3 (hyclate) in the solvent of choice, which should be purged with an inert gas. Doxycycline-d₃ (hyclate) is slightly soluble in DMSO and methanol.

Description

Doxycycline is a broad-spectrum tetracycline antibiotic. 1,2 It inhibits bacterial protein synthesis by binding to ribosomes.^{2,3} Doxycycline also selectively inhibits human matrix metalloproteinase-8 (MMP-8) and MMP-13 over MMP-1 with 50, 60, and 5% inhibition, respectively, when used at a concentration of 30 μ M. It can be used as a regulator for inducible gene expression systems where expression depends on either the presence (Tet-On) or absence (Tet-Off) of doxycycline.^{5,6} Formulations containing doxycycline have been used in the treatment of bacterial infections and the prevention of malaria.

References

- 1. Williamson, G.M. Chemotherapia (Basel) 13(Suppl. 1), 1-6 (1968).
- 2. Griffin, M.O., Ceballos, G., and Villarreal, F.J. Pharmacol. Res. 63(2), 102-107 (2011).
- 3. Chopra, I. Antimicrob. Agents Chemother. 38(4), 637-640 (1994).
- Smith, G.N., Jr., Mickler, E.A., Hasty, K.A., et al. Arthritis Rheum. 42(6), 1140-1146 (1999).
- 5. Gould, D.J., Berenstein, M., Dreja, H., et al. Gene Ther. 7(24), 2061-2070 (2000).
- Li, Z., Michael, I.P., Zhou, D., et al. Proc. Natl. Acad. Sci. USA 110(13), 5004-5009 (2013).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 12/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM